---

EUSA will have marketed products, and full infrastructure and sales force in key European markets, and modest operations and sales in the United States.  Their assets include four specialty products:  Caphosol for oral mucositis, Collatamp for post-operative infections, Custodial for organ transport, and Xenazine for movement disorders.

Transaction Summary

• Essex Woodlands is backing Bryan Morton, the former CEO of EUSA Pharma, in a proprietary deal to acquire several key assets of his old company to serve as a platform for a buy-and-build strategy. Bryan Morton followed a similar strategy at EUSA Pharma, a successful Fund VII growth equity deal.
• We seek to transform the company into a fast growing trans-Atlantic specialty pharmaceutical company through acquiring and in-licensing products and companies with European revenue to leverage the current European infrastructure, as well as acquiring and in-licensing EU and US rights to specialty products that are in late-stage clinical trials and could be launched within three years to accelerate revenue growth.
• Essex Woodlands made its first investment in EUSA Pharma (II) in 2015.

• Hemel Hempstead, United Kingdom


• Contact:
  Petri Vainio
  Evis Hursever
  
• www.eusapharma.com

Related News

• EUSA Pharma Announces Acquisition of Global Rights to SYLVANT (siltuximab) from Janssen Sciences Ire
• EUSA Pharma Appoints Industry Veteran Rolf K Hoffmann to its Board of Directors
• EUSA Pharma and AVEO Oncology Announce First Commercial Launch of FOTIVDA (tivozanib)
• EUSA Pharma Receives Positive CHMP Opinion for Tivozanib for First-Line Treatment


“EW Healthcare Partners is not so much an Investor as a Partner in building successful businesses as was my experience with EUSA Pharma.”

Bryan Morton

Chairman, EUSA Pharma